Try our Investor Tool
Login
Sign Up
Login
Sign Up
Features
Pricing
Reg.News
Contact
Try our Investor Tool
Login
Sign Up
Search
Providers
Companies
⨯
LIVE
Event in Progress:
Join Here
×
Search
Providers
Companies
⨯
Features
Pricing
Event Hub
Reg.News
Short Interest
Contact
All the news articles and press releases in one place.
UK Reg. News
German Reg. News
Key Announcements
Results / Trading Updates
Get free RNS email alerts for@Model.CurrentFilterValue
Currently filtered for Allergy Therapeutics plc
Clear Filter
Search
Sector
Automobile Industry
Banks
Basic Materials
Building & Construction
Chemicals
Consumer Discretionary Goods
Consumer Discretionary Services
Consumer Staple Goods
Consumer Staple Services
Discretionary Personal Goods
Discretionary Retail
Energy
ETFs
Finance
Financial Services
Food & Drink
Food Production
Health
Household Goods & DIY
Industrial
Industrial Equipment, Goods & Services
Insurance & Reinsurance
Investment Trusts
Leisure, Tourism & Travel
Media
Open-ended Funds
Other
Real Estate
Resources
Staple Retail
Technology
Telecoms
Trusts, ETFs & Funds
Utilities
Market Cap
Below £20m
£20m - £100m
£100m - £300m
£300m - £1bn
£1bn - £10bn
Over £10bn
Filters »
All
UK100
UK250
UK SmallCap
UK Other
Show:
10
25
50
100
«
1
2
»
Date / Time
Source
Company
Sector
Market Cap
Announcement
03Mar23 07:00
RNS
Allergy Therapeutics plc
Health
£42.4m
Allergy Therapeutics - PDMR Dealing
07Feb23 18:29
RNS
Allergy Therapeutics plc
Health
£42.4m
Allergy Therapeutics - Result of AGM
20Jan23 07:00
RNS
Allergy Therapeutics plc
Health
£42.4m
Allergy Therapeutics - Half-Year Trading Update 2023
13Jan23 17:27
RNS
Allergy Therapeutics plc
Health
£42.4m
Allergy Therapeutics - NOTICE OF 2022 ANNUAL GENERAL MEETING
03Jan23 07:30
RNS
Allergy Therapeutics plc
Health
£42.4m
AIM - Suspension - Allergy Therapeutics plc
29Dec22 07:00
RNS
Allergy Therapeutics plc
Health
£42.4m
Allergy Therapeutics - Annual Report and Accounts Delayed
28Dec22 07:00
RNS
Allergy Therapeutics plc
Health
£42.4m
Allergy Therapeutics - Director Resignation
08Dec22 07:00
RNS
Allergy Therapeutics plc
Health
£42.4m
Allergy Therapeutics - Key updates on Grass MATA MPL and VLP Peanut
06Dec22 07:00
RNS
Allergy Therapeutics plc
Health
£42.4m
Allergy Therapeutics - Appointment of Non-Executive Directors
21Nov22 07:00
RNS
Allergy Therapeutics plc
Health
£42.4m
Allergy Therapeutics - Appointment of Interim CFO
28Oct22 07:00
RNS
Allergy Therapeutics plc
Health
£42.4m
Allergy Therapeutics - Allergy to resume UK manufacturing production
19Oct22 15:39
RNS
Allergy Therapeutics plc
Health
£42.4m
Allergy Therapeutics - Holding(s) in Company
17Oct22 13:27
RNS
Allergy Therapeutics plc
Health
£42.4m
Allergy Therapeutics - Allergy Therapeutics – Result of GM
04Oct22 07:00
RNS
Allergy Therapeutics plc
Health
£42.4m
Allergy Therapeutics - UK manufacturing update
29Sep22 12:00
RNS
Allergy Therapeutics plc
Health
£42.4m
Allergy Therapeutics - Allergy Therapeutics at Investor Meet Company
29Sep22 07:00
RNS
Allergy Therapeutics plc
Health
£42.4m
Allergy Therapeutics - Unaudited Preliminary Results 2022
29Sep22 07:00
RNS
Allergy Therapeutics plc
Health
£42.4m
Allergy Therapeutics - Subscription and Debt Financing
05Sep22 07:00
RNS
Allergy Therapeutics plc
Health
£42.4m
Allergy Therapeutics - Allergy Therapeutics at H.C. Wainwright Conference
02Sep22 16:50
RNS
Allergy Therapeutics plc
Health
£42.4m
Allergy Therapeutics - Total Voting Rights
15Jul22 07:00
RNS
Allergy Therapeutics plc
Health
£42.4m
Allergy Therapeutics - Trading Update and Notice of Results
01Jul22 07:00
RNS
Allergy Therapeutics plc
Health
£42.4m
Allergy Therapeutics - Allergy Therapeutics at EAACI Congress 2022
26May22 07:00
RNS
Allergy Therapeutics plc
Health
£42.4m
Allergy Therapeutics - Nick Wykeman to step down as CFO
23May22 07:00
RNS
Allergy Therapeutics plc
Health
£42.4m
Allergy Therapeutics - Allergy Therapeutics at H.C. Wainwright Conference
25Apr22 07:00
RNS
Allergy Therapeutics plc
Health
£42.4m
Allergy Therapeutics - Allergy Therapeutics shares data at WAO-BSACI
08Mar22 07:00
RNS
Allergy Therapeutics plc
Health
£42.4m
Allergy Therapeutics - Allergy Therapeutics at Cowen Health Conference
07Mar22 07:00
RNS
Allergy Therapeutics plc
Health
£42.4m
Allergy Therapeutics - Allergy Therapeutics at Investor Meet Company
03Mar22 07:00
RNS
Allergy Therapeutics plc
Health
£42.4m
Allergy Therapeutics - Allergy Therapeutics plc – Interim Results
01Mar22 07:00
RNS
Allergy Therapeutics plc
Health
£42.4m
Allergy Therapeutics - Allergy Therapeutics shares positive new data
02Feb22 11:05
RNS
Allergy Therapeutics plc
Health
£42.4m
Allergy Therapeutics - Secures new revolving credit facility
01Feb22 14:16
RNS
Allergy Therapeutics plc
Health
£42.4m
Allergy Therapeutics - Total Voting Rights
26Jan22 07:00
RNS
Allergy Therapeutics plc
Health
£42.4m
Allergy Therapeutics - FDA clearance of IND application for VLP Peanut
24Jan22 13:13
RNS
Allergy Therapeutics plc
Health
£42.4m
Allergy Therapeutics - Holding(s) in Company
13Jan22 07:00
RNS
Allergy Therapeutics plc
Health
£42.4m
Allergy Therapeutics - Half Year Trading Update & Notice of Results
05Jan22 08:47
RNS
Allergy Therapeutics plc
Health
£42.4m
Allergy Therapeutics - Total Voting Rights
25Nov21 09:17
RNS
Allergy Therapeutics plc
Health
£42.4m
Allergy Therapeutics - Allergy Therapeutics: Granting of Awards
23Nov21 12:54
RNS
Allergy Therapeutics plc
Health
£42.4m
Allergy Therapeutics - Result of AGM
11Nov21 07:00
RNS
Allergy Therapeutics plc
Health
£42.4m
Allergy Therapeutics - Director Dealings
27Oct21 07:00
RNS
Allergy Therapeutics plc
Health
£42.4m
Allergy Therapeutics - Cheryl MacDiarmid appointed to Board of Directors
25Oct21 07:00
RNS
Allergy Therapeutics plc
Health
£42.4m
Allergy Therapeutics - Allergy announces positive G309 results
14Oct21 09:24
RNS
Allergy Therapeutics plc
Health
£42.4m
Allergy Therapeutics - Holding(s) in Company
07Oct21 16:37
RNS
Allergy Therapeutics plc
Health
£42.4m
Allergy Therapeutics - Annual Report and AGM Notification
23Sep21 07:00
RNS
Allergy Therapeutics plc
Health
£42.4m
Allergy Therapeutics - Preliminary Results for Year ended 30 June 2021
16Sep21 07:00
RNS
Allergy Therapeutics plc
Health
£42.4m
Allergy Therapeutics - ImmunoBON voted Most Innovative Product of 2021
13Sep21 07:00
RNS
Allergy Therapeutics plc
Health
£42.4m
Allergy Therapeutics - Secondary endpoints from VLP Peanut 001
09Sep21 07:00
RNS
Allergy Therapeutics plc
Health
£42.4m
Allergy Therapeutics - Allergy to Present at H.C. Wainwright Conference
07Sep21 07:00
RNS
Allergy Therapeutics plc
Health
£42.4m
Allergy Therapeutics - Allergy to host KOL webinar on VLP Peanut
03Aug21 07:00
RNS
Allergy Therapeutics plc
Health
£42.4m
Allergy Therapeutics - Successful primary outcome of VLP Peanut 001
02Aug21 10:57
RNS
Allergy Therapeutics plc
Health
£42.4m
Allergy Therapeutics - Total Voting Rights
14Jul21 07:00
RNS
Allergy Therapeutics plc
Health
£42.4m
Allergy Therapeutics - Trading update for the year ended 30 June 2021
08Jul21 07:00
RNS
Allergy Therapeutics plc
Health
£42.4m
Allergy Therapeutics - AGY to present key scientific findings at EAACI
24Jun21 07:00
RNS
Allergy Therapeutics plc
Health
£42.4m
Allergy Therapeutics - Trading Update
01Jun21 15:36
RNS
Allergy Therapeutics plc
Health
£42.4m
Allergy Therapeutics - Total Voting Rights
06May21 07:00
RNS
Allergy Therapeutics plc
Health
£42.4m
Completion of treatment phase in G309 study
30Apr21 17:47
RNS
Allergy Therapeutics plc
Health
£42.4m
Total Voting Rights
16Apr21 07:00
RNS
Allergy Therapeutics plc
Health
£42.4m
Appointment of new Group auditors
31Mar21 08:29
RNS
Allergy Therapeutics plc
Health
£42.4m
Vesting of Awards under Long Term Incentive Plan
26Mar21 16:39
RNS
Allergy Therapeutics plc
Health
£42.4m
Pledge of Shares
11Mar21 12:13
RNS
Allergy Therapeutics plc
Health
£42.4m
Pledge of Shares
08Mar21 07:00
RNS
Allergy Therapeutics plc
Health
£42.4m
AGY to Present at H.C. Wainwright Conference
03Mar21 07:00
RNS
Allergy Therapeutics plc
Health
£42.4m
Interim Results for six months ended 31 Dec 2020
13Jan21 07:00
RNS
Allergy Therapeutics plc
Health
£42.4m
Half Year Trading Update 2021 & Notice of Results
05Jan21 07:00
RNS
Allergy Therapeutics plc
Health
£42.4m
Initiation of peanut allergy biomarker study
14Dec20 15:58
RNS
Allergy Therapeutics plc
Health
£42.4m
Director/PDMR Shareholding
08Dec20 14:42
RNS
Allergy Therapeutics plc
Health
£42.4m
Result of Annual General Meeting
20Nov20 13:51
RNS
Allergy Therapeutics plc
Health
£42.4m
Grant of Awards under Long Term Incentive Plan
20Nov20 07:00
RNS
Allergy Therapeutics plc
Health
£42.4m
Director/PDMR Shareholding
10Nov20 07:05
RNS
Allergy Therapeutics plc
Health
£42.4m
Annual Report & Accounts and AGM Notification
26Oct20 07:00
RNS
Allergy Therapeutics plc
Health
£42.4m
Initiation of Grass MATA MPL exploratory study
12Oct20 07:00
RNS
Allergy Therapeutics plc
Health
£42.4m
Holding(s) in Company
09Oct20 07:00
RNS
Allergy Therapeutics plc
Health
£42.4m
Director Dealings and Issue of Equity
23Sep20 07:00
RNS
Allergy Therapeutics plc
Health
£42.4m
Preliminary Results
03Sep20 07:00
RNS
Allergy Therapeutics plc
Health
£42.4m
AGY secures VLP technology platform
20Jul20 07:30
EQS
Allergy Therapeutics plc
Health
£42.4m
Hardman & Co Research: Allergy Therapeutics (AGY): Record sales and a COVID-19 wildcard
15Jul20 07:00
RNS
Allergy Therapeutics plc
Health
£42.4m
Trading Update
09Jul20 07:00
RNS
Allergy Therapeutics plc
Health
£42.4m
Invalidation of Birch MATA MPL phase III results
01Jul20 17:15
RNS
Allergy Therapeutics plc
Health
£42.4m
Total Voting Rights
24Jun20 07:00
RNS
Allergy Therapeutics plc
Health
£42.4m
Trading Update
22Apr20 10:11
RNS-R
Allergy Therapeutics plc
Health
£42.4m
EAACI review of adjuvants and formulations
01Apr20 13:09
RNS
Allergy Therapeutics plc
Health
£42.4m
Grant and Vesting of Awards
09Mar20 07:15
EQS
Allergy Therapeutics plc
Health
£42.4m
Hardman & Co Research: Allergy Therapeutics (AGY): Consistent first-half revenue growth
04Mar20 07:00
RNS
Allergy Therapeutics plc
Health
£42.4m
Half-year Report
29Jan20 12:00
RNS
Allergy Therapeutics plc
Health
£42.4m
Data for peanut allergy vaccine published in JACI
16Jan20 12:25
RNS
Allergy Therapeutics plc
Health
£42.4m
Trading Update & Notice of Results - Replacement
16Jan20 08:00
EQS
Allergy Therapeutics plc
Health
£42.4m
Hardman & Co Research: Allergy Therapeutics (AGY): Sales growth well above market average
16Jan20 07:00
RNS
Allergy Therapeutics plc
Health
£42.4m
Half Year Trading Update & Notice of Results
02Dec19 09:57
RNS
Allergy Therapeutics plc
Health
£42.4m
Holdings in Company
29Nov19 10:34
RNS
Allergy Therapeutics plc
Health
£42.4m
Holdings in Company
26Nov19 07:00
RNS
Allergy Therapeutics plc
Health
£42.4m
Update to Grass MATA MPL Ph III clinical programme
25Nov19 12:13
RNS
Allergy Therapeutics plc
Health
£42.4m
Result of Annual General Meeting
22Oct19 09:23
RNS
Allergy Therapeutics plc
Health
£42.4m
Annual Report and Accounts
26Sep19 07:30
EQS
Allergy Therapeutics plc
Health
£42.4m
Hardman & Co Research: Allergy Therapeutics (AGY): Continuing to gain market share
25Sep19 07:00
RNS
Allergy Therapeutics plc
Health
£42.4m
Preliminary Results
11Jul19 07:00
RNS
Allergy Therapeutics plc
Health
£42.4m
Trading update
01Jul19 07:21
EQS
Allergy Therapeutics plc
Health
£42.4m
Hardman & Co Research: Allergy Therapeutics (AGY): Successful legal outcome removes uncertainty
01Jul19 07:16
EQS
Allergy Therapeutics plc
Health
£42.4m
Hardman & Co Research: Oxford BioMedica (OXB): Eying up long-term value
27Jun19 07:00
RNS
Allergy Therapeutics plc
Health
£42.4m
Successful Litigation Settlement
27Jun19 07:00
RNS
Allergy Therapeutics plc
Health
£42.4m
Trading Statement
19Jun19 07:00
RNS
Allergy Therapeutics plc
Health
£42.4m
Board Change
11Jun19 07:00
RNS
Allergy Therapeutics plc
Health
£42.4m
Holdings in Company
21May19 08:30
EQS
Allergy Therapeutics plc
Health
£42.4m
Hardman & Co Research: Titon Holdings Plc (TON): You need hands
«
1
2
»
Date / Time
Source
Company
% Chg
03Mar23 07:00
RNS
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - PDMR Dealing
07Feb23 18:29
RNS
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - Result of AGM
20Jan23 07:00
RNS
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - Half-Year Trading Update 2023
13Jan23 17:27
RNS
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - NOTICE OF 2022 ANNUAL GENERAL MEETING
03Jan23 07:30
RNS
Allergy Therapeutics plc
0.00%
AIM - Suspension - Allergy Therapeutics plc
29Dec22 07:00
RNS
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - Annual Report and Accounts Delayed
28Dec22 07:00
RNS
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - Director Resignation
08Dec22 07:00
RNS
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - Key updates on Grass MATA MPL and VLP Peanut
06Dec22 07:00
RNS
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - Appointment of Non-Executive Directors
21Nov22 07:00
RNS
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - Appointment of Interim CFO
28Oct22 07:00
RNS
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - Allergy to resume UK manufacturing production
19Oct22 15:39
RNS
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - Holding(s) in Company
17Oct22 13:27
RNS
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - Allergy Therapeutics – Result of GM
04Oct22 07:00
RNS
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - UK manufacturing update
29Sep22 12:00
RNS
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - Allergy Therapeutics at Investor Meet Company
29Sep22 07:00
RNS
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - Unaudited Preliminary Results 2022
29Sep22 07:00
RNS
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - Subscription and Debt Financing
05Sep22 07:00
RNS
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - Allergy Therapeutics at H.C. Wainwright Conference
02Sep22 16:50
RNS
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - Total Voting Rights
15Jul22 07:00
RNS
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - Trading Update and Notice of Results
01Jul22 07:00
RNS
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - Allergy Therapeutics at EAACI Congress 2022
26May22 07:00
RNS
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - Nick Wykeman to step down as CFO
23May22 07:00
RNS
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - Allergy Therapeutics at H.C. Wainwright Conference
25Apr22 07:00
RNS
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - Allergy Therapeutics shares data at WAO-BSACI
08Mar22 07:00
RNS
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - Allergy Therapeutics at Cowen Health Conference
07Mar22 07:00
RNS
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - Allergy Therapeutics at Investor Meet Company
03Mar22 07:00
RNS
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - Allergy Therapeutics plc – Interim Results
01Mar22 07:00
RNS
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - Allergy Therapeutics shares positive new data
02Feb22 11:05
RNS
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - Secures new revolving credit facility
01Feb22 14:16
RNS
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - Total Voting Rights
26Jan22 07:00
RNS
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - FDA clearance of IND application for VLP Peanut
24Jan22 13:13
RNS
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - Holding(s) in Company
13Jan22 07:00
RNS
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - Half Year Trading Update & Notice of Results
05Jan22 08:47
RNS
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - Total Voting Rights
25Nov21 09:17
RNS
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - Allergy Therapeutics: Granting of Awards
23Nov21 12:54
RNS
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - Result of AGM
11Nov21 07:00
RNS
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - Director Dealings
27Oct21 07:00
RNS
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - Cheryl MacDiarmid appointed to Board of Directors
25Oct21 07:00
RNS
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - Allergy announces positive G309 results
14Oct21 09:24
RNS
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - Holding(s) in Company
07Oct21 16:37
RNS
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - Annual Report and AGM Notification
23Sep21 07:00
RNS
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - Preliminary Results for Year ended 30 June 2021
16Sep21 07:00
RNS
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - ImmunoBON voted Most Innovative Product of 2021
13Sep21 07:00
RNS
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - Secondary endpoints from VLP Peanut 001
09Sep21 07:00
RNS
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - Allergy to Present at H.C. Wainwright Conference
07Sep21 07:00
RNS
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - Allergy to host KOL webinar on VLP Peanut
03Aug21 07:00
RNS
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - Successful primary outcome of VLP Peanut 001
02Aug21 10:57
RNS
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - Total Voting Rights
14Jul21 07:00
RNS
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - Trading update for the year ended 30 June 2021
08Jul21 07:00
RNS
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - AGY to present key scientific findings at EAACI
24Jun21 07:00
RNS
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - Trading Update
01Jun21 15:36
RNS
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - Total Voting Rights
06May21 07:00
RNS
Allergy Therapeutics plc
0.00%
Completion of treatment phase in G309 study
30Apr21 17:47
RNS
Allergy Therapeutics plc
0.00%
Total Voting Rights
16Apr21 07:00
RNS
Allergy Therapeutics plc
0.00%
Appointment of new Group auditors
31Mar21 08:29
RNS
Allergy Therapeutics plc
0.00%
Vesting of Awards under Long Term Incentive Plan
26Mar21 16:39
RNS
Allergy Therapeutics plc
0.00%
Pledge of Shares
11Mar21 12:13
RNS
Allergy Therapeutics plc
0.00%
Pledge of Shares
08Mar21 07:00
RNS
Allergy Therapeutics plc
0.00%
AGY to Present at H.C. Wainwright Conference
03Mar21 07:00
RNS
Allergy Therapeutics plc
0.00%
Interim Results for six months ended 31 Dec 2020
13Jan21 07:00
RNS
Allergy Therapeutics plc
0.00%
Half Year Trading Update 2021 & Notice of Results
05Jan21 07:00
RNS
Allergy Therapeutics plc
0.00%
Initiation of peanut allergy biomarker study
14Dec20 15:58
RNS
Allergy Therapeutics plc
0.00%
Director/PDMR Shareholding
08Dec20 14:42
RNS
Allergy Therapeutics plc
0.00%
Result of Annual General Meeting
20Nov20 13:51
RNS
Allergy Therapeutics plc
0.00%
Grant of Awards under Long Term Incentive Plan
20Nov20 07:00
RNS
Allergy Therapeutics plc
0.00%
Director/PDMR Shareholding
10Nov20 07:05
RNS
Allergy Therapeutics plc
0.00%
Annual Report & Accounts and AGM Notification
26Oct20 07:00
RNS
Allergy Therapeutics plc
0.00%
Initiation of Grass MATA MPL exploratory study
12Oct20 07:00
RNS
Allergy Therapeutics plc
0.00%
Holding(s) in Company
09Oct20 07:00
RNS
Allergy Therapeutics plc
0.00%
Director Dealings and Issue of Equity
23Sep20 07:00
RNS
Allergy Therapeutics plc
0.00%
Preliminary Results
03Sep20 07:00
RNS
Allergy Therapeutics plc
0.00%
AGY secures VLP technology platform
20Jul20 07:30
EQS
Allergy Therapeutics plc
0.00%
Hardman & Co Research: Allergy Therapeutics (AGY): Record sales and a COVID-19 wildcard
15Jul20 07:00
RNS
Allergy Therapeutics plc
0.00%
Trading Update
09Jul20 07:00
RNS
Allergy Therapeutics plc
0.00%
Invalidation of Birch MATA MPL phase III results
01Jul20 17:15
RNS
Allergy Therapeutics plc
0.00%
Total Voting Rights
24Jun20 07:00
RNS
Allergy Therapeutics plc
0.00%
Trading Update
22Apr20 10:11
RNS-R
Allergy Therapeutics plc
0.00%
EAACI review of adjuvants and formulations
01Apr20 13:09
RNS
Allergy Therapeutics plc
0.00%
Grant and Vesting of Awards
09Mar20 07:15
EQS
Allergy Therapeutics plc
0.00%
Hardman & Co Research: Allergy Therapeutics (AGY): Consistent first-half revenue growth
04Mar20 07:00
RNS
Allergy Therapeutics plc
0.00%
Half-year Report
29Jan20 12:00
RNS
Allergy Therapeutics plc
0.00%
Data for peanut allergy vaccine published in JACI
16Jan20 12:25
RNS
Allergy Therapeutics plc
0.00%
Trading Update & Notice of Results - Replacement
16Jan20 08:00
EQS
Allergy Therapeutics plc
0.00%
Hardman & Co Research: Allergy Therapeutics (AGY): Sales growth well above market average
16Jan20 07:00
RNS
Allergy Therapeutics plc
0.00%
Half Year Trading Update & Notice of Results
02Dec19 09:57
RNS
Allergy Therapeutics plc
0.00%
Holdings in Company
29Nov19 10:34
RNS
Allergy Therapeutics plc
0.00%
Holdings in Company
26Nov19 07:00
RNS
Allergy Therapeutics plc
0.00%
Update to Grass MATA MPL Ph III clinical programme
25Nov19 12:13
RNS
Allergy Therapeutics plc
0.00%
Result of Annual General Meeting
22Oct19 09:23
RNS
Allergy Therapeutics plc
0.00%
Annual Report and Accounts
26Sep19 07:30
EQS
Allergy Therapeutics plc
0.00%
Hardman & Co Research: Allergy Therapeutics (AGY): Continuing to gain market share
25Sep19 07:00
RNS
Allergy Therapeutics plc
0.00%
Preliminary Results
11Jul19 07:00
RNS
Allergy Therapeutics plc
0.00%
Trading update
01Jul19 07:21
EQS
Allergy Therapeutics plc
0.00%
Hardman & Co Research: Allergy Therapeutics (AGY): Successful legal outcome removes uncertainty
01Jul19 07:16
EQS
Allergy Therapeutics plc
0.00%
Hardman & Co Research: Oxford BioMedica (OXB): Eying up long-term value
27Jun19 07:00
RNS
Allergy Therapeutics plc
0.00%
Successful Litigation Settlement
27Jun19 07:00
RNS
Allergy Therapeutics plc
0.00%
Trading Statement
19Jun19 07:00
RNS
Allergy Therapeutics plc
0.00%
Board Change
11Jun19 07:00
RNS
Allergy Therapeutics plc
0.00%
Holdings in Company
21May19 08:30
EQS
Allergy Therapeutics plc
0.00%
Hardman & Co Research: Titon Holdings Plc (TON): You need hands
«
1
2
»
Date / Time
Company
% Chg
03Mar23 07:00
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - PDMR Dealing
07Feb23 18:29
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - Result of AGM
20Jan23 07:00
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - Half-Year Trading Update 2023
13Jan23 17:27
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - NOTICE OF 2022 ANNUAL GENERAL MEETING
03Jan23 07:30
Allergy Therapeutics plc
0.00%
AIM - Suspension - Allergy Therapeutics plc
29Dec22 07:00
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - Annual Report and Accounts Delayed
28Dec22 07:00
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - Director Resignation
08Dec22 07:00
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - Key updates on Grass MATA MPL and VLP Peanut
06Dec22 07:00
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - Appointment of Non-Executive Directors
21Nov22 07:00
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - Appointment of Interim CFO
28Oct22 07:00
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - Allergy to resume UK manufacturing production
19Oct22 15:39
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - Holding(s) in Company
17Oct22 13:27
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - Allergy Therapeutics – Result of GM
04Oct22 07:00
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - UK manufacturing update
29Sep22 12:00
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - Allergy Therapeutics at Investor Meet Company
29Sep22 07:00
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - Unaudited Preliminary Results 2022
29Sep22 07:00
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - Subscription and Debt Financing
05Sep22 07:00
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - Allergy Therapeutics at H.C. Wainwright Conference
02Sep22 16:50
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - Total Voting Rights
15Jul22 07:00
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - Trading Update and Notice of Results
01Jul22 07:00
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - Allergy Therapeutics at EAACI Congress 2022
26May22 07:00
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - Nick Wykeman to step down as CFO
23May22 07:00
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - Allergy Therapeutics at H.C. Wainwright Conference
25Apr22 07:00
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - Allergy Therapeutics shares data at WAO-BSACI
08Mar22 07:00
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - Allergy Therapeutics at Cowen Health Conference
07Mar22 07:00
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - Allergy Therapeutics at Investor Meet Company
03Mar22 07:00
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - Allergy Therapeutics plc – Interim Results
01Mar22 07:00
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - Allergy Therapeutics shares positive new data
02Feb22 11:05
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - Secures new revolving credit facility
01Feb22 14:16
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - Total Voting Rights
26Jan22 07:00
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - FDA clearance of IND application for VLP Peanut
24Jan22 13:13
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - Holding(s) in Company
13Jan22 07:00
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - Half Year Trading Update & Notice of Results
05Jan22 08:47
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - Total Voting Rights
25Nov21 09:17
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - Allergy Therapeutics: Granting of Awards
23Nov21 12:54
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - Result of AGM
11Nov21 07:00
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - Director Dealings
27Oct21 07:00
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - Cheryl MacDiarmid appointed to Board of Directors
25Oct21 07:00
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - Allergy announces positive G309 results
14Oct21 09:24
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - Holding(s) in Company
07Oct21 16:37
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - Annual Report and AGM Notification
23Sep21 07:00
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - Preliminary Results for Year ended 30 June 2021
16Sep21 07:00
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - ImmunoBON voted Most Innovative Product of 2021
13Sep21 07:00
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - Secondary endpoints from VLP Peanut 001
09Sep21 07:00
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - Allergy to Present at H.C. Wainwright Conference
07Sep21 07:00
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - Allergy to host KOL webinar on VLP Peanut
03Aug21 07:00
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - Successful primary outcome of VLP Peanut 001
02Aug21 10:57
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - Total Voting Rights
14Jul21 07:00
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - Trading update for the year ended 30 June 2021
08Jul21 07:00
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - AGY to present key scientific findings at EAACI
24Jun21 07:00
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - Trading Update
01Jun21 15:36
Allergy Therapeutics plc
0.00%
Allergy Therapeutics - Total Voting Rights
06May21 07:00
Allergy Therapeutics plc
0.00%
Completion of treatment phase in G309 study
30Apr21 17:47
Allergy Therapeutics plc
0.00%
Total Voting Rights
16Apr21 07:00
Allergy Therapeutics plc
0.00%
Appointment of new Group auditors
31Mar21 08:29
Allergy Therapeutics plc
0.00%
Vesting of Awards under Long Term Incentive Plan
26Mar21 16:39
Allergy Therapeutics plc
0.00%
Pledge of Shares
11Mar21 12:13
Allergy Therapeutics plc
0.00%
Pledge of Shares
08Mar21 07:00
Allergy Therapeutics plc
0.00%
AGY to Present at H.C. Wainwright Conference
03Mar21 07:00
Allergy Therapeutics plc
0.00%
Interim Results for six months ended 31 Dec 2020
13Jan21 07:00
Allergy Therapeutics plc
0.00%
Half Year Trading Update 2021 & Notice of Results
05Jan21 07:00
Allergy Therapeutics plc
0.00%
Initiation of peanut allergy biomarker study
14Dec20 15:58
Allergy Therapeutics plc
0.00%
Director/PDMR Shareholding
08Dec20 14:42
Allergy Therapeutics plc
0.00%
Result of Annual General Meeting
20Nov20 13:51
Allergy Therapeutics plc
0.00%
Grant of Awards under Long Term Incentive Plan
20Nov20 07:00
Allergy Therapeutics plc
0.00%
Director/PDMR Shareholding
10Nov20 07:05
Allergy Therapeutics plc
0.00%
Annual Report & Accounts and AGM Notification
26Oct20 07:00
Allergy Therapeutics plc
0.00%
Initiation of Grass MATA MPL exploratory study
12Oct20 07:00
Allergy Therapeutics plc
0.00%
Holding(s) in Company
09Oct20 07:00
Allergy Therapeutics plc
0.00%
Director Dealings and Issue of Equity
23Sep20 07:00
Allergy Therapeutics plc
0.00%
Preliminary Results
03Sep20 07:00
Allergy Therapeutics plc
0.00%
AGY secures VLP technology platform
20Jul20 07:30
Allergy Therapeutics plc
0.00%
Hardman & Co Research: Allergy Therapeutics (AGY): Record sales and a COVID-19 wildcard
15Jul20 07:00
Allergy Therapeutics plc
0.00%
Trading Update
09Jul20 07:00
Allergy Therapeutics plc
0.00%
Invalidation of Birch MATA MPL phase III results
01Jul20 17:15
Allergy Therapeutics plc
0.00%
Total Voting Rights
24Jun20 07:00
Allergy Therapeutics plc
0.00%
Trading Update
22Apr20 10:11
Allergy Therapeutics plc
0.00%
EAACI review of adjuvants and formulations
01Apr20 13:09
Allergy Therapeutics plc
0.00%
Grant and Vesting of Awards
09Mar20 07:15
Allergy Therapeutics plc
0.00%
Hardman & Co Research: Allergy Therapeutics (AGY): Consistent first-half revenue growth
04Mar20 07:00
Allergy Therapeutics plc
0.00%
Half-year Report
29Jan20 12:00
Allergy Therapeutics plc
0.00%
Data for peanut allergy vaccine published in JACI
16Jan20 12:25
Allergy Therapeutics plc
0.00%
Trading Update & Notice of Results - Replacement
16Jan20 08:00
Allergy Therapeutics plc
0.00%
Hardman & Co Research: Allergy Therapeutics (AGY): Sales growth well above market average
16Jan20 07:00
Allergy Therapeutics plc
0.00%
Half Year Trading Update & Notice of Results
02Dec19 09:57
Allergy Therapeutics plc
0.00%
Holdings in Company
29Nov19 10:34
Allergy Therapeutics plc
0.00%
Holdings in Company
26Nov19 07:00
Allergy Therapeutics plc
0.00%
Update to Grass MATA MPL Ph III clinical programme
25Nov19 12:13
Allergy Therapeutics plc
0.00%
Result of Annual General Meeting
22Oct19 09:23
Allergy Therapeutics plc
0.00%
Annual Report and Accounts
26Sep19 07:30
Allergy Therapeutics plc
0.00%
Hardman & Co Research: Allergy Therapeutics (AGY): Continuing to gain market share
25Sep19 07:00
Allergy Therapeutics plc
0.00%
Preliminary Results
11Jul19 07:00
Allergy Therapeutics plc
0.00%
Trading update
01Jul19 07:21
Allergy Therapeutics plc
0.00%
Hardman & Co Research: Allergy Therapeutics (AGY): Successful legal outcome removes uncertainty
01Jul19 07:16
Allergy Therapeutics plc
0.00%
Hardman & Co Research: Oxford BioMedica (OXB): Eying up long-term value
27Jun19 07:00
Allergy Therapeutics plc
0.00%
Successful Litigation Settlement
27Jun19 07:00
Allergy Therapeutics plc
0.00%
Trading Statement
19Jun19 07:00
Allergy Therapeutics plc
0.00%
Board Change
11Jun19 07:00
Allergy Therapeutics plc
0.00%
Holdings in Company
21May19 08:30
Allergy Therapeutics plc
0.00%
Hardman & Co Research: Titon Holdings Plc (TON): You need hands
«
1
2
»
Strapline
Strapline
Question 1
Answer 1
Question 2
Answer 2
Question 3
Answer 3
Question 4
Answer 4
Question 5
Answer 5
Question 6
Answer 6
Question 7
Answer 7
Question 8
Answer 8
Top
Home
Features
Pricing
Event Hub
Reg.News
Short Interest Tracker
Blogs
Academy
Insights
News
Research Tree
The Naked Fund Manager
Ideas & Picks
Ideas Hub
Stock Pick League
Explore Content
Regions
UK
Rest of EMEA
N America
APAC
LatAm
Exchanges
Aquis Apex
Australian Securities Exchange
Canadian Securities Exchange
Euronext Paris
London Stock Exchange (domestic)
SIX Swiss Exchange
Sectors
Automobile Industry
Banks
Building & Construction
Chemicals
Discretionary Personal Goods
Discretionary Retail
Energy
ETFs
Financial Services
Food & Drink
Food Production
Health
Household Goods & DIY
Industrial Equipment, Goods & Services
Insurance & Reinsurance
Investment Trusts
Leisure, Tourism & Travel
Media
Open-ended Funds
Other
Real Estate
Resources
Staple Retail
Technology
Telecoms
Utilities
AIC Sectors
Asia Pacific
Asia Pacific Equity Income
Asia Pacific Smaller Companies
Biotechnology & Healthcare
China / Greater China
Commodities & Natural Resources
Country Specialist
Debt - Direct Lending
Debt - Loans & Bonds
Debt - Structured Finance
Environmental
Europe
European Smaller Companies
Farmland & Forestry
Financials
Flexible Investment
Global
Global Emerging Markets
Global Equity Income
Global Smaller Companies
Growth Capital
Hedge Funds
India
Infrastructure
Infrastructure Securities
Insurance & Reinsurance Strategies
Japan
Japanese Smaller Companies
Latin America
Leasing
Liquidity Funds
North America
North American Smaller Companies
Private Equity
Property - Debt
Property - Europe
Property - Rest of World
Property - UK Commercial
Property - UK Logistics
Property - UK Residential
Property Securities
Renewable Energy Infrastructure
Technology & Media
UK All Companies
UK Equity & Bond Income
UK Equity Income
UK Smaller Companies
VCT AIM Quoted
VCT Generalist
VCT Generalist Pre Qualifying
VCT Specialist: Environmental
VCT Specialist: Environmental Pre Qualifying
VCT Specialist: Healthcare & Biotechnology
Trust Managers
3i Group
3i Investments
Aberforth Partners
abrdn
AEW UK Investment Management
Albion Capital
Allianz Global Investors
Alpha Real Capital
Amati Global Investors
Amedeo Air Four Plus
Apax Guernsey Managers
Aquila Capital Investment
Artemis Investment Management
Asset Value Investors
Athelney Trust
Atrato Partners Limited
Augmentum Capital
Axiom Alternative Investments
Baillie Gifford
Baker Steel Capital
Beringea
BlackRock Investment Management (UK)
Boussard & Gavaudan Asset Management
Brevan Howard Capital Management
Chelverton Asset Management
Columbia Threadneedle
CVC Credit Partners
Doric Partners
Ecofin
Fidelity
Foresight Group
Frostrow Capital
Fundsmith
Gravis Capital Management
Greencoat Capital
Gresham House
Hansa Capital Partners
Harwood Capital
ICM
InfraRed Capital Partners
Invesco Asset Management
J.P. Morgan Asset Management
Janus Henderson Investors
Jupiter Unit Trust Managers
KKV Investment Management
Liontrust Asset Management
Markel CATCo Investment Management
Maven Capital Partners
MD Barnard and Co
Mercia Asset Management
Montanaro Investment Managers
Neuberger Berman Europe
New City Investment Managers
Octopus Investments
Pantheon Ventures
Phoenix Asset Management
Polar Capital Holdings
Premier Miton
Puma Investments
Quaero Capital
Rampart Capital
Ravenscroft
Riverstone International
Schroder Investment Management
Schroder Real Estate Management
Seneca Investment Managers
Triple Point Investment Management
Tritax Management
Troy Asset Management
TwentyFour Asset Management
White Oak Capital Partners
Willis Towers Watson
YFM Private Equity
Small / Large Cap
UK100
UK250
UK Smallcap
UK Other Main Markets
Other
Private/EIS
EIS Single Company
EIS/SEIS Funds
IHT Products
SEIS Single Company
VCT Funds
Providers
Free/Commissioned
ACF Equity Research
Align Research
BRR Media
Calvine Partners
Capital Access Group
Checkpoint Partners
Clear Capital Markets
Couloir Capital
Doceo
Edison
Equity Development
eResearch
Fidante Partners
Five Minute Pitch TV
goetzpartners securities Limited
Hardman & Co
Inbound Capital
Independent Investment Research
InterAxS Global
Kepler | Trust Intelligence
London Stock Exchange
Magnitogorsk Iron and steel works
Mello Events
Mining Network
piworld.co.uk
Proactive
Progressive Equity Research
Quantum Research Group
QuotedData
RaaS - Research as a Service
Radnor Capital Partners
Research Tree
SEAL Advisors Ltd
ShareSoc
The AIC
Trinity Delta
UK Investor Group
Vox Markets
Yellowstone Advisory
High Net Worth Offering
Fox-Davies Capital
ACF Equity Research
Allenby Capital
AlphaValue
Alternative Resource Capital
Arctic Securities
Arden Partners
Auctus Advisors
Baptista Research
BNP Paribas Exane - Sponsored Research
Canaccord Genuity
Cenkos Securities
Couloir Capital
Dowgate Capital
finnCap
First Berlin
First Sentinel
Hannam & Partners
Hybridan
Kemeny Capital
Liberum
Longspur Research
Louis Capital
Magnitogorsk Iron and steel works
Medley Global Advisors
Northland Capital Partners
QuotedData Professional
Shard Capital
ShareSoc
Shore Capital
Singer Capital Markets
SP Angel
Stanford Capital Partners
Stifel FirstEnergy
Stockdale Securities
Tamesis Partners
The Life Sciences Division
VSA Capital
WHIreland
Whitman Howard
Yellowstone Advisory
Zeus Capital
Institutional Offering
Fox-Davies Capital
ACF Equity Research
Align Research
Allenby Capital
AlphaValue
Alternative Resource Capital
Arctic Securities
Arden Partners
Atrium Research
Auctus Advisors
Baptista Research
BNP Paribas Exane
BNP Paribas Exane - Sponsored Research
BRR Media
Bryan, Garnier & Co
Calderwood Capital
Calvine Partners
Canaccord Genuity
Capital Access Group
Cenkos Securities
Checkpoint Partners
Clear Capital Markets
Couloir Capital
Doceo
Dowgate Capital
Edison
Equity Development
eResearch
Fidante Partners
finnCap
First Berlin
First Sentinel
Five Minute Pitch TV
goetzpartners securities Limited
Hannam & Partners
Hardman & Co
Hybridan
Hypothesis Research
Inbound Capital
Independent Investment Research
InterAxS Global
Kemeny Capital
Kepler | Absolute Hedge
Kepler | Trust Intelligence
Liberum
London Stock Exchange
Longspur Research
Magnitogorsk Iron and steel works
Mello Events
Mining Network
Northland Capital Partners
Numis
Panmure Gordon
Peel Hunt
piworld.co.uk
Proactive
Progressive Equity Research
Quantum Research Group
QuotedData
RaaS - Research as a Service
Radnor Capital Partners
Research Tree
Resolve Research
SEAL Advisors Ltd
Shard Capital
ShareSoc
Shore Capital
SI Capital
Singer Capital Markets
SP Angel
Stanford Capital Partners
Stifel
Stifel FirstEnergy
Stockdale Securities
Tamesis Partners
The AIC
The Life Sciences Division
Trinity Delta
UK Investor Group
Velocity Trade
Vox Markets
VSA Capital
WHIreland
Whitman Howard
Winterflood Securities
Yellowstone Advisory
Zeus Capital
Video/Audio Interviews
BRR Media
Capital Access Group
Couloir Capital
Doceo
Edison
Equity Development
Five Minute Pitch TV
Mining Network
piworld.co.uk
Proactive
QuotedData
RaaS - Research as a Service
Research Tree
UK Investor Group
Vox Markets
Yellowstone Advisory
Event Providers
Capital Access Group
Cenkos Securities
Couloir Capital
Edison
Equity Development
Hardman & Co
InterAxS Global
Kepler | Trust Intelligence
London Stock Exchange
Mello Events
piworld.co.uk
Proactive
QuotedData
Research Tree
ShareSoc
The AIC
UK Investor Group
VSA Capital
Yellowstone Advisory
Contact
Sign Up
Sign In
Share: